While clinical trials involving OVs such as MV-NIS, Reolysin, and VSV-IFNβ-NIS in MM have shown acceptable safety profiles, with responses ranging from partial remission to disease stabilization, the risk of latent viral infections or recombination remains a concern (29, 44, 61–64, 110). This evidence concerns the gene SLC5A5 and Miyoshi myopathy.